openPR Logo
Press release

Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma

07-11-2024 11:54 PM CET | Health & Medicine

Press release from: ABNewswire

Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead

DelveInsight's, "Osteoarthritis Pipeline Insight 2024" report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Osteoarthritis treatment drugs @ Osteoarthritis Pipeline Outlook [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Osteoarthritis Pipeline Report

* June 2024:- New Approaches to Neuroblastoma Therapy Consortium- Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial. This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
* DelveInsight's Osteoarthritis pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis treatment.
* The leading Osteoarthritis Companies working in the market include Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
* Promising Osteoarthritis Therapies in the various stages of development include E1K 1,200 joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.

Find out more about Osteoarthritis treatment drugs @ Drugs for Osteoarthritis Treatment [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Osteoarthritis Emerging Drugs Profile

* Lorecivivint: Biosplice Therapeutics
* CYP 004: Cynata Therapeutics
* JTA-004: Bone Therapeutics
* SMUP-IA-01: Medipost
* TTAX03: Tissue Tech

Osteoarthritis Therapeutics Assessment

There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.

DelveInsight's Osteoarthritis pipeline report covers around 130+ products under different phases of Osteoarthritis clinical trials development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Learn more about the emerging Osteoarthritis pipeline therapies @ Osteoarthritis Clinical Trials [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Intravenous
* Subcutaneous

Osteoarthritis Products have been categorized under various Molecule types such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

Osteoarthritis Companies

Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.

Dive deep into rich insights for new drugs for Osteoarthritis Treatment, visit @ New Osteoarthritis Drugs [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Osteoarthritis Pipeline Report

* Coverage- Global
* Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
* Osteoarthritis Therapies- E1K 1,200 /joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.

For further information on the Osteoarthritis Pipeline Therapeutics, reach out @ Osteoarthritis Treatment Drugs [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Osteoarthritis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Osteoarthritis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lorecivivint: Biosplice Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TTAX03: Tissue Tech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* GLPG-0555: Gilead Sciences
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Protego-PD: Plakous Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Osteoarthritis Key Companies
* Osteoarthritis Key Products
* Osteoarthritis- Unmet Needs
* Osteoarthritis- Market Drivers and Barriers
* Osteoarthritis- Future Perspectives and Conclusion
* Osteoarthritis Analyst Views
* Osteoarthritis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoarthritis-pipeline-2024-biosplice-therapeutics-gilead-sciences-flexion-therapeutics-glaxosmithkline-levicept-arthrogen-personalized-stem-cells-peptinov-asahi-kasei-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma here

News-ID: 3577571 • Views:

More Releases from ABNewswire

The Science of Sharper Thinking: Sustainable Ways to Support Memory and Mental Performance
The Science of Sharper Thinking: Sustainable Ways to Support Memory and Mental P …
In an economy powered by ideas, clarity of thought is a competitive edge. The ability to retain information, connect patterns, recall details, and stay focused under pressure influences everything from leadership decisions to academic achievement. Memory is no longer just a background cognitive function-it's central to productivity, creativity, and long-term success. In an economy powered by ideas, clarity of thought is a competitive edge. The ability to retain information, connect patterns,
Travel-Loving Women Find Their Perfect Beach Style With Beach Groove Swimwear's Diverse Collections
Travel-Loving Women Find Their Perfect Beach Style With Beach Groove Swimwear's …
Beach Groove Swimwear caters to the modern travel enthusiast with versatile swimwear collections designed for various vacation scenarios. From tropical getaways to poolside parties, the brand offers women a comprehensive selection that combines fashion-forward designs with practical performance features. For women who prioritize travel and beach experiences, finding the right swimwear can make or break a vacation. Beach Groove Swimwear has emerged as a specialized retailer that understands the unique needs
How J&J Accessories Uses Customer Behavior Analytics to Stay Ahead of Retail Trends
How J&J Accessories Uses Customer Behavior Analytics to Stay Ahead of Retail Tre …
In an era where many retailers struggle with excess inventory and declining margins, J&J Accessories has built a thriving e-commerce business by letting data guide every product decision. The company's analytical approach to understanding customer behavior has enabled it to maintain a fresh, relevant catalog that resonates with time-pressed professionals. This strategy positions the brand as a model for the next generation of agile online retail. The retail industry has long
Small Business Champion Rnispir LLC Showcases Products from Veteran and Women-Owned Enterprises Nationwide
Small Business Champion Rnispir LLC Showcases Products from Veteran and Women-Ow …
Rnispir LLC is making waves in the e-commerce sector by prioritizing partnerships with underrepresented business owners across America. With a network exceeding 400 U.S. suppliers, the company spotlights products from veterans, women entrepreneurs, and family operations, offering customers distinctive gourmet foods, outdoor equipment, and home goods unavailable through conventional retail channels. The American small business landscape faces unprecedented challenges, from supply chain disruptions to competition with multinational corporations. Rnispir LLC addresses

All 5 Releases


More Releases for Osteoarthritis

Osteoarthritis Market Massive Growth opportunity Ahead
Introduction Osteoarthritis (OA), the most common form of arthritis, remains a significant global health burden, causing pain, mobility limitations, and reduced quality of life for millions. Driven by an aging population, lifestyle-related factors like obesity, and a growing focus on musculoskeletal health, the osteoarthritis market is witnessing notable transformation. According to Exactitude Consultancy, the global osteoarthritis market was valued at USD 14 billion in 2024 and is projected to reach USD 22
Rising Sports Injuries Fuel Growth In Osteoarthritis Therapeutics Market: The Dr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Osteoarthritis Therapeutics Market Size Growth Forecast: What to Expect by 2025? In recent times, the osteoarthritis therapeutics market has seen substantial growth. The market size was $8.17 billion in 2024 and is projected to rise to $8.87 billion in 2025, reflecting an annual compound growth rate (CAGR) of 8.6%.
Osteoarthritis Treatment Market Trends and Forecast 2034
On March 20, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Osteoarthritis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across
Osteoarthritis Treatment Market
Introduction Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide. It is a degenerative joint disease that primarily impacts the cartilage and causes pain, stiffness, and reduced mobility. The growing prevalence of osteoarthritis, especially among the aging population, has created a significant demand for treatment options. The osteoarthritis treatment market includes various therapeutic approaches, such as medications, physical therapies, and surgical procedures, designed to manage the symptoms and
Osteoarthritis Therapeutics Market - Finding Freedom from Osteoarthritis: Discov …
Newark, New Castle, USA: The "Osteoarthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Osteoarthritis Therapeutics Market: https://www.growthplusreports.com/report/osteoarthritis-therapeutics-market/7779 This latest report researches the industry structure, sales, revenue,
Osteoarthritis Therapeutics Market: Rising Obese and Geriatric Populations to In …
Industry is experiencing significant growth due to the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment is likely to hamper the growth of the market. What the Osteoarthritis Therapeutics Market Looks Like? The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8